Showing 11-20 of 43 results for "".
Find Your Niche
https://practicaldermatology.com/topics/practice-management/find-your-niche/19078/Jay A. Shorr, BA, MBM-C, CAC I-V and Mara Shorr, BS, CAC II-V of The Best Medical Business Solutions offer tips for setting yourself and your practice apart. Develop your specialization, build a reputation, and you won't have to compete on price or rely on marketing gimmicks.To Sell or Not to Sell to Private Equity?
https://practicaldermatology.com/conferences/scale-2023/to-sell-or-not-to-sell-to-private-equity/20195/Joel L. Cohen, MD, and George Hruza MD, discuss the pros and cons of selling to private equity. Pros include back-office support and better pricing on technology and supplies, while cons can include giving up autonomy.- Dermira Prices Initial Public Offeringhttps://practicaldermatology.com/news/20141003-dermira_prices_initial_public_offering/2459096/Dermira will price its initial public offering of 7,812,500 shares of common stock at a price to the public of 16 dollars per share. The shares are expected to begin trading on The NASDAQ Global Select Market on October 3, 2014 under the symbol DERM.Citigroup and Leerink Partners are acti
- Valeant's Patient Access And Pricing Committee Announces Pricing For SILIQ as Lowest Priced Injectable Biologic For Psoriasishttps://practicaldermatology.com/news/valeants-patient-access-and-pricing-committee-announces-pricing-for-siliq-as-lowest-priced-injectable-biologic-for-psoriasis/2458215/Following the evaluation and approval of its Patient Access and Pricing Committee (PAPC), Valeant Pharmaceuticals International, Inc. has decided to list SILIQ (brodalumab) injection at $3,500 per month, which is the lowest injectable biologic psoriasis treatment cur
- Aclaris Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/aclaris-announces-pricing-of-initial-public-offering/2458854/Aclaris Therapeutics, Inc. announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price to the public of $11.00 per share. The shares, approved for listing on The NASDAQ Global Select Market, will be traded under the ticker symbol ACRS. All of the common
- Revance Therapeutics Announces Pricing of Initial Public Offeringhttps://practicaldermatology.com/news/20140207-revance_therapeutics_announces_pricing_of_initial_public_offering/2459346/Revance Therapeutics, Inc., a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced the pricing of its initial public offering of 6,000,000 shares of its common stock at a public offering price of $16.00 per share, befo
- Cynthia Nixon Partners with Galderma and the NRS to Raise Awareness for Rosaceahttps://practicaldermatology.com/news/20130314-cynthia_nixon_partners_with_galderma_and_the_nrs_to_raise_awareness_for_rosacea/2459591/Actress Cynthia Nixon recently joined with dermatologists Rick Fried, MD and Flor Mayoral, MD and a panel of other experts at the "Face to Face with Rosacea: Empowering Professionals and Patients" educational event at the AAD Meeting in Miami. Sponsored by Galderma in conjunction with the National R
- Study Finds Increasing Prices for Prescription Dermatology Drugs Since 2009https://practicaldermatology.com/news/study-finds-increasing-prices-for-prescription-dermatology-drugs-since-2009/2458800/A recent study published in JAMA Dermatology found that the price of prescription dermatologic drugs rose considerably from 2009 to 2015, with the vast majority of price increases occurring after 2011. In an effo
- Foamix Pharmaceuticals Announces Upsizing and Pricing of Its Public Offeringhttps://practicaldermatology.com/news/foamix-pharmaceuticals-announces-upsizing-and-pricing-of-its-public-offering/2458968/Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), a specialty pharmaceutical company focused on developing topical foams to address unmet needs in dermatology, today announced the pricing of an upsized public offering of 6,451,612 ordinary shares at a price to the public of $9.30 per share. In addition,
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A